Assuming conservative lecanemab uptake rates of 1.1–2.9% for an estimated 82,000 to 208,000 of eligible people, current vial sizes would lead to an estimated $133 million to $336 million worth ...

The treatment was approved in 2024 for chronic graft-vs-host disease after failure of at least 2 prior lines of systemic therapy in patients weighing at least 40kg. The Food and Drug ...

Eli Lilly and Company is unveiling its new 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, which will be available for $499 per month using its new Zepbound Self Pay Journey Program. 1 The ...

Current vial sizes may result in 5.8% of the Alzheimer's disease drug being thrown away, representing $1,619 in wasted ...